1,720,970 research outputs found
Forest plot of the meta-analysis of fibrate use and cancer deaths.
No full text<p>Footnote: The risk ratios and their 95% confidence intervals are displayed on a logarithmic scale. The size of the data markers represents the relative weight of the trial according to size and occurrence of the outcome being measured.</p
Characteristics of studies included in the meta-analysis.
No full text<p>Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; BECAIT, Bezafibrate Coronary Atherosclerosis Intervention Trial; BIP, Bezafibrate Infarction Prevention; CDP, Coronary Drug Project; DAIS, Diabetes Atherosclerosis Intervention Study; DIS, Diabetes Intervention Study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; HHS, Helsinki Heart Study; LEADER, Lower Extremity Arterial Disease Event Reduction; LOCAT, Lopid Coronary Angiography Trial; SENDCAP, St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention; VA HIT, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial; WHO, World Health Organization; r, randomized; db, double-blind; pc, placebo-controlled; DM, Diabetes Mellitus; CAD, Coronary Artery Disease; NIDDM, Non-Insulin-Dependent Diabetes Mellitus; LEAD, Lower Extremity Arterial Disease.</p
Incidence of and/or deaths from cancer in the randomized placebo-controlled trials of fibrates.
No full text*<p>Crude rates;</p>**<p>Reported in Saha et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0045259#pone.0045259-Saha1" target="_blank">[43]</a>.</p><p>Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; BECAIT, Bezafibrate Coronary Atherosclerosis Intervention Trial; BIP, Bezafibrate Infarction Prevention; CDP, Coronary Drug Project; DAIS, Diabetes Atherosclerosis Intervention Study; DIS, Diabetes Intervention Study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; HHS, Helsinki Heart Study; LEADER, Lower Extremity Arterial Disease Event Reduction; LOCAT, Lopid Coronary Angiography Trial; SENDCAP, St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention; VA HIT, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial; WHO, World Health Organization; RR, relative risk (risk ratio); CI, confidence interval.</p
Fibrate use and cancer deaths: Subgroup analyses.
No full text<p>Fibrate use and cancer deaths: Subgroup analyses.</p
Flow Diagram.
No full text<p>Footnote: * To be included in this meta-analysis, studies had to be (i) randomized trials of fibrates, (ii) placebo-controlled, and (iii) have a mean (or median) duration of patient follow-up of at least 2 years.</p
Meta-regression’s results.
No full text<p>RR, risk ratio; CI, confidence interval.</p><p>Results are exponentiated regression coefficients and their 95% CIs, which show the proportional change in risk ratio for every one scale increase.</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Forest plot of the meta-analysis of fibrate use and cancer incidence.
No full text<p>Footnote: The risk ratios and their 95% confidence intervals are displayed on a logarithmic scale. The size of the data markers represents the relative weight of the trial according to size and occurrence of the outcome being measured.</p
Fibrate use and cancer incidence: Subgroup analyses.
No full text<p>Fibrate use and cancer incidence: Subgroup analyses.</p
- …
